Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 825-832

  Mayer, F ^a   Honecker, F ^b   Looijenga, L H J ^b   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Cell cycle control; Chemotherapy resistance; Cisplatin; Germ cell tumors

Indexed keywords

ABC TRANSPORTER; CISPLATIN; DNA; GLUTATHIONE; GLYCOPROTEIN P; PROTEIN P53; VALSPODAR;

ANEUPLOIDY; APOPTOSIS; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; GERM CELL TUMOR; HUMAN; MISMATCH REPAIR; PRIORITY JOURNAL; REVIEW; TELOMERE; TERATOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GERMINOMA; HUMANS; MALE; TESTICULAR NEOPLASMS;

EID: 0038350314     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg242     Document Type: Review

References (66)

1. Mostofi FK. Proceedings: testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 1973; 32: 1186-1201.
2. Bokemeyer C, Nichols CR, Droz JP et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002; 20: 1864-1873.
3. Pottern ML, Brown M, Devesa SS. Epidemiology and pathogenesis of testicular cancer. In Ernsthoff MS, Heaney JA, Peschel RE (eds): Testicular and Penile Cancer. Oxford. UK: Blackwell Science 1998; 2-10.
4. Jørgensen N, Rajpert-De Meyts E, Graem N et al. Expression of immunohistochemical markets for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest 1995; 72: 223-231.
5. Mostofi FK, Sesterhenn IA. Revised international histological classification of testicular tumors. Adv Biosci 1993; 91: 153-158.
6. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002; 99: 4592-4595.
7. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001; 19: 2647-2657.
8. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
9. Kollmannsberger C, Mayer F. Kuczyk M et al. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. World J Urol 2001; 19: 120-125.
10. Ishida S, Lee J, Thiele DJ et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctrl in yeast and mammals. Proc Natl Acad Sci USA 2002; 99: 14298-14302.
11. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001: 478: 23-43.
12. Borst P, Evers R, Kool M et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
13. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001; 7: 935-941.
14. Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-758.
15. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998; 10 (Suppl 1): S15-S19.
16. Scheffer GL, Schroeijers AB, Izquierdo MA et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000; 12: 550-556.
17. Izquierdo MA, Scheffer GL, Flens MJ et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148: 877-887.
18. Mayer F, Stoop H, Scheffer GL et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003; 9: 767-773.
19. Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2). MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-3547.
20. Jansen BA. Brouwer J, Reedijk J. Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 2002; 89: 197-202.
21. Masters JR, Thomas R, Hall AG et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996; 32A: 1248-1253.
22. Koropatnick J, Kloth DM, Kadhim S et al. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J Pharmacol Exp Ther 1995; 275: 1681-1687.
23. Sark MW, Timmer-Bosscha H, Meijer C et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 1995; 71: 684-690.
24. Meijer C, Timmer A, De Vries EG et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 2000; 85: 777-781.
25. Strohmeyer T, Klone A, Wagner G et al. Glutathione S-transferases in human testicular germ cell tumors: changes of expression and activity. J Urol 1992; 147: 1424-1428.
26. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
27. Koberle B, Grimaldi KA, Sunters A et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997; 70: 551-555.
28. Koberle B, Payne J, Grimaldi KA et al. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 1996; 52: 1729-1734.
29. Koberle B, Masters JR. Hartley JA et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-276.
30. Zamble DB, Mikata Y, Eng CH et al. Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J Inorg Biochem 2002; 91: 451-462.
31. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000; 461: 83-108.
32. Robertson KA, Bullock HA, Xu Y et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001; 61: 2220-2225.
33. Bernstein C, Bernstein H, Payne CM et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 145-178.
34. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
35. Aebi S, Kurdi-Haidar B, Gordon R et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-3090.
36. Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999; 125: 156-165.
37. Lothe RA, Peltomaki P, Tommerup N et al. Molecular genetic changes in human male germ cell tumors. Lab Invest 1995; 73: 606-614.
38. Devouassoux-Shisheboran M, Mauduit C, Bouvier R et al. Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours. Mol Hum Reprod 2001; 7: 1099-1105.
39. Mayer F, Gillis AJ, Dinjens W et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002; 62: 2758-2760.
40. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
41. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med 1996; 2: 804-810.
42. Lutzker SG, Mathew R, Taller DR. A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells. Oncogene 2001; 20: 2982-2986.
43. Burger H, Nooter K, Boersma AW et al. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 1997; 73: 592-599.
44. Burger H, Nooter K, Boersma AW et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999; 81: 620-628.
45. Houldsworth J, Xiao H, Murty VV et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998; 16: 2345-2349.
46. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592.
47. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996; 56: 1834-1841.
48. Burger H, Nooter K, Boersma AW et al. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 1998; 77: 1562-1567.
49. Baltaci S, Orhan D, Turkolmez K et al. P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours. BJU Int 2001; 87: 661-666.
50. Richards EH, Hickey E, Weber L et al. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 1996; 56: 2446-2451.
51. Roelofs H, Mostert MC, Pompe K et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 2000; 157: 1155-1166.
52. Moorehead RA, Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000; 59: 337-345.
53. Bonovich M, Olive M, Reed E et al. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002; 9: 62-70.
54. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 2000; 97: 14295-14300.
55. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci USA 2001; 98: 11283-11288.
56. Oosterhuis JW, Castedo SM, de Jong B et al. Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance. Lab Invest 1989; 60: 14-21.
57. Looijenga LHJ, Oosterhuis JW, Ramaekers FC et al. Dual parameter flow cytometry for deoxyribonucleic acid and intermediate filament proteins of residual mature teratoma. All tumor cells are aneuploid. Lab Invest 1991; 64: 113-117.
58. van Echten J, de Jong B, Sinke RJ et al. Definition of a new entity of malignant extragonadal germ cell tumors. Genes Chromosom Cancer 1995; 12: 8-15.
59. Albanell J, Bosl GJ, Reuter VE et al. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 1999; 91: 1321-1326.
60. Kiyozuka Y, Yamamoto D, Yang J et al. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 2000; 20: 203-212.
61. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 1998; 95: 4219-4223.
62. Burger AM, Double JA, Newell DR. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Ent J Cancer 1997; 33: 638-644.
63. Cressey TR, Tilby MJ, Newell DR. Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Eur J Cancer 2002; 38: 586-593.
64. Comerford KM, Wallace TJ, Karhausen J et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDRI) gene. Cancer Res 2002; 62: 3387-3394.
65. Pluquet O, Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 2001; 174: 1-15.
66. Strohmeyer T, Reissmann P, Cordon-Cardo C et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 1991; 88: 6662-6666.